United Kingdom· GB-APID-42593411000001100
Eylea 30.1mg/263microlitres solution for injection vials
A aflibercept product containing aflibercept, registered in United Kingdom by Bayer Plc. The same ATC class is registered in 11 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Aflibercept is registered in 11 of 19 countries.
Countries holding a registration under ATC L01XX44 (aflibercept), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Aflibercept · ATC L01XX44
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Aflibercept
- Manufacturer
- Bayer Plc
- Country
- United Kingdom (GB)
- ATC code
- L01XX44
- ATC class
- Aflibercept
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin5010605402999
- gtin5010605404085
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
70 interactions on record for aflibercept.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aflibercept · interactions on record
70 records
- 29 severe
- 41 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aflibercept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandAfivegSTADA Arzneimittel AG
- CzechiaAFIVEGSTADA Arzneimittel AG, Bad Vilbel
- BelgiumAfiveg 40 mg/mlStada Arzneimittel
- SwedenAfiveg 40 mg/ml Injektionsvätska, lösningSTADA Arzneimittel AG
- IcelandAfivegSTADA Arzneimittel AG
- SpainAFQLIR 40 MG/ML SOLUCION INYECTABLE EN JERINGA PRECARGADASandoz Gmbh
- NetherlandsAfiveg 40 mg/ml oplossing voor injectieStada Arzneimittel AG
- IrelandAfiveg 40 mg/mL solution for injectionStada Arzneimittel AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Afiveg, Afqlir
- Liechtenstein · Afiveg, Afqlir
- Norway · Afiveg, Afqlir
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fecf4821-b99f-434b-9c8b-81c56f22edf6 GET /v1/drugs/fecf4821-b99f-434b-9c8b-81c56f22edf6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42593411000001100",
"desc": "Eylea 30.1mg/263microlitres solution for injection vials (Bayer Plc)",
"form": "Solution for injection",
"vpid": "42603511000001107",
"source": "dmd",
"vtm_id": "774443007",
"strength": "114.3 mg",
"substance": "Aflibercept",
"ingredient": "Aflibercept",
"supplier_code": "2063701000001109"
}See everything about aflibercept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.